drugs for overactive bladder (OAB)

GTx Announces Preliminary Results with Enobosarm

GTx, Inc. (Nasdaq: GTXI) today announced release of preliminary clinical data from its ongoing, open-label, Phase 2 clinical trial of enobosarm 3 mg (GTx-024) in postmenopausal women with stress urinary incontinence (SUI). An abstract entitled “Kegels In A Bottle”: Preliminary Results Of A Selective Androgen Receptor Modulator (GTx-024) For The Treatment Of SUI In Post-Menopausal Women, summarizing clinical data from the first seven patients completing 12 weeks of treatment with enobosarm, is now available on the International Continence Society’s website. This proof-of-concept clinical trial is the first of its kind to evaluate an orally-administered selective androgen receptor modulator (SARM) for SUI. Read more.

Source: BusinessWire, June 12, 2017

Hormone Changes in Women

hormones change as women age

Hormone changes occur  throughout a woman’s life time.

Women have the hormone estrogen in their body. Estrogen helps develop female characteristics, and is responsible for your monthly period by causing the lining of your uterus to build up before being released every 28 days or so.  Estrogen also helps your pelvic floor to be strong, supple and stretchy, which gives you greater control over your bladder and bowel function. Stress urinary incontinence is the most common type of incontinence experienced as a result of a loss of tissue strength from declining estrogen levels in the peri (before) and post (after) menopausal stage of life. Prior pelvic floor injury from multiple or traumatic vaginal deliveries tends to contribute to a higher incidence of stress urinary incontinence in menopause. Estrogen depletion can contribute to more urgency, frequency of urination (OAB) and sometimes urge urinary incontinence.Continue reading